
Clinical trials
Studies registered on ClinicalTrials.gov, anchored to the NCT number.
42 cards, each checked against its primary source
Search the catalogWhat this catalog holds
Clinical trials testing anti-ageing interventions in people. Each has an NCT number, phase and status, so you can see where the study stands.
Two scales on every card
How strong the evidence is, and how close it is to people. A result in mice with strong methods is still a result in mice — the two answers are shown separately so neither hides the other.
Closeness to humans
Strongest evidence
AllNCT04867616. Bepranemab (UCB0107) in prodromal to mild Alzheimer's disease
Phase 2NCT04867616
Completed phase 2 trial sponsored by UCB Biopharma SRL. Primary completion 24 May 2024. The Lancet Neurology report (PMID 43008775) says the CDR-SB primary endpoint was not met.
1 news item
PURIFY-TIMI 81 (YN001)
Phase 2NCT07521007
Phase 2b, N≈456, randomized double-blind placebo-controlled; primary endpoint relative change coronary noncalcified plaque volume.
1 news item
DASL-HiCaP (ANZUP1801): darolutamide with ADT and radiotherapy in very high-risk localised prostate cancer
Phase 3NCT04136353
Randomised double-blind placebo-controlled phase 3 trial led by the University of Sydney and ANZUP. Interim analysis presented at ESMO 2026 (24 October 2026): metastasis-free survival HR 0.42 (95% CI 0.27-0.66) at median 3.8 years; overall survival not yet different.
1 news item
Axes of longevity
Cards are tagged with the hallmarks of aging they touch.
- Genomic instability
- Telomere attrition
- Epigenetic alterations
- Loss of proteostasis
- Disabled macroautophagy
- Deregulated nutrient sensing
- Mitochondrial dysfunction
- Cellular senescence
- Stem cell exhaustion
- Altered intercellular communication
- Chronic inflammation
- Dysbiosis
Classification: López-Otín C. et al. Hallmarks of aging: An expanding universe. Cell, 2023.
Search the catalog
Filters
Closeness to humans
Closeness to humans:Any
Order:Newest
Card descriptions are written in Russian for now; English text is coming.
NCT04867616. Bepranemab (UCB0107) in prodromal to mild Alzheimer's disease
Phase 2NCT04867616
Completed phase 2 trial sponsored by UCB Biopharma SRL. Primary completion 24 May 2024. The Lancet Neurology report (PMID 43008775) says the CDR-SB primary endpoint was not met.
1 news item
DASL-HiCaP (ANZUP1801): darolutamide with ADT and radiotherapy in very high-risk localised prostate cancer
Phase 3NCT04136353
Randomised double-blind placebo-controlled phase 3 trial led by the University of Sydney and ANZUP. Interim analysis presented at ESMO 2026 (24 October 2026): metastasis-free survival HR 0.42 (95% CI 0.27-0.66) at median 3.8 years; overall survival not yet different.
1 news item
MSK-DA01 (bemdaneprocel) phase 1 in advanced Parkinson's disease
Phase 1NCT04802733
Open-label phase 1 safety and tolerability study of MSK-DA01 (bemdaneprocel), sponsored by BlueRock Therapeutics, in 12 patients with advanced Parkinson's disease. Results published by Tabar et al., Nature 2025 (PMID 40240592).
1 news item
ASPIRO (ANPD001) — autologous iPSC-derived cells in Parkinson's disease
Phase 1NCT06344026
Open-label phase 1/2a study sponsored by Aspen Neuroscience: dopamine-neuron precursor cells made from each participant's own reprogrammed skin cells, with planned dose escalation in about 9 adults aged 40 to 75. Primary outcome: safety at one year. Enrolling by invitation.
1 news item
exPDite-2 (bemdaneprocel) in Parkinson's disease
Phase 3NCT06944522
Phase 3 trial sponsored by BlueRock Therapeutics, designed to randomise about 102 adults aged 45 to 75 with Parkinson's disease 2:1 to bemdaneprocel or sham surgery, with participants, investigators and assessors blinded. Primary outcome: daily time with good symptom control and without troublesome dyskinesia (patient diary) at 78 weeks.
1 news item
PrevenTRON (trontinemab) in preclinical Alzheimer’s
Phase 3NCT07717411
Международная Phase 3 по предотвращению Alzheimer до симптомов.
No news yet
Urolithin A vs placebo (NIA)
NCT06274749
≥55 лет, BMI≥27, n=180, triple-mask, инсулиновая секреция на 4 и 8 неделях.
No news yet
IB1001-303 (levacetylleucine in ataxia-telangiectasia)
NCT06673056
Underlying trial for FDA approval of AQNEURSA in A-T; результаты опубликованы в Lancet Neurology, июль 2026.
No news yet
AV-1959R vaccine in preclinical Alzheimer’s disease
Phase 2NCT07827768
160 участников 55–80 лет, когнитивно сохранных, с биомаркерными признаками preclinical AD; randomized double-blind placebo-controlled.
No news yet
REGEND001 in emphysematous COPD
Phase 3NCT07828353
Planned 102 участника, multicenter randomized blinded placebo-controlled; из собственных airway basal stem cells пациента.
No news yet
First-in-human: autologous bone-marrow MSC infusion in severe osteoporosis
NCT02566655
10 женщин 51–72 лет, однократная внутривенная инфузия собственных bone-marrow mesenchymal stromal cells; Cell, 11 сентября.
No news yet
Finerenone vs placebo in premature ovarian insufficiency
Phase 2NCT07815509
План 46 участниц; primary endpoint — доля женщин, у которых удастся получить ооциты при IVF в течение 24 недель.
No news yet
PIEZO-101 (Piezo Therapeutics)
Early phase 1NCT07671027
Плазмидный DNA-биостимулятор; Early Phase 1, ожидаемая дата старта 1 сентября 2026.
No news yet
SELECT (semaglutide 2.4 mg), frailty post-hoc analysis
NCT03574597
Post-hoc RCT analysis, n=17 604, JAMA Cardiology 16.09.2026.
No news yet
SECURE polypill
NCT02596126
Aspirin + ramipril + atorvastatin vs usual care after recent MI, median 36 months, primary MACE HR 0.76 (0.60–0.96). Castellano et al. N Engl J Med 2022;387:967-977.
No news yet
SOUL (oral semaglutide)
NCT03914326
McGuire DK et al. N Engl J Med 2025;392:2001-2012.
No news yet
FIDELIO-DKD (finerenone)
NCT02540993
Advanced T2D + albuminuric CKD; Bakris et al., N Engl J Med 2020;383:2219–2229.
No news yet
FINEARTS-HF (finerenone)
NCT04435626
HFmrEF / HFpEF; Solomon et al., N Engl J Med 2024;391:1475–1485.
No news yet
Ezetimibe and plasma appearance of oral 7-KC bolus
NCT00794677
Concerns absorption PK, not lesion clearance or plaque imaging.
No news yet
PAC-MAN (LDL-like nanoparticle paclitaxel)
NCT04148833
Tolerated, no significant between-group CTA plaque benefit in a small pilot.
No news yet
CARAT (CER-001)
NCT02484378
CER-001, IV pre-beta HDL mimetic: no incremental IVUS PAV benefit vs placebo on statin-era care.
No news yet
IMPROVE-IT
NCT00202878
18,144 post-ACS patients randomized to simvastatin+ezetimibe vs simvastatin+placebo.
No news yet
PRECISE-IVUS
NCT01043380
Randomized atorvastatin vs atorvastatin+ezetimibe with serial coronary IVUS, 202 patients.
No news yet
CLEAR HIV (bempedoic acid)
Phase 2NCT05488431
Randomized placebo-controlled mechanistic Phase 2 in people with treated HIV; FDG-PET/CT arterial inflammation outcomes.
No news yet